Lode-Star Mining Inc. announced that in connection with the acquisition of Sapir Pharmaceuticals Inc. it has appointed Dr. Liora Zilberson as a member of the Board of Directors and acting Chief Executive Officer effective February 21, 2022. In addition to her engagement Dr. Zilberson will receive 10,000,000 shares of the Company's common stock. Dr. Zilberson has been with Sapir since April of 2017 where she has been the director of CMC (drug chemistry, manufacturing and controls) Operations and Project Management.

From January 2015 through March 2017, she was the Chief Executive Officer at N2B (Nose to Brain), a company that developed treatment for Parkinson's disease via intranasal means. From 2010 through 2014, Dr. Zilberson was the international market project manager at Teva Pharmaceutical, and from 2004 through 2010 she worked in the research and development department.